A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Clinical trial NCT07318883 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07318883
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2031-01-01
- Enrollment
- 720
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.